<--- Back to Details
First PageDocument Content
Non-small-cell lung carcinoma / Immunotherapy / Cancer / PD-1 / Targeted therapy / Metastasis / Carcinogenesis / Bevacizumab / Galena Biopharma / Medicine / Lung cancer / Cancer treatments
Date: 2015-02-03 02:46:54
Non-small-cell lung carcinoma
Immunotherapy
Cancer
PD-1
Targeted therapy
Metastasis
Carcinogenesis
Bevacizumab
Galena Biopharma
Medicine
Lung cancer
Cancer treatments

Microsoft Word - 150202_PDL-1_final_en

Add to Reading List

Source URL: www.roche.com

Download Document from Source Website

File Size: 105,12 KB

Share Document on Facebook

Similar Documents

# 3083 AGI-134, a fully synthetic α-Gal-based cancer immunotherapy that shows synergy with anti-PD-1 and favorable pre-clinical pharmacokinetic and toxicity profiles Sascha A. Kristian 1,*,#, Stephen M. Shaw 1,*, Kim Wi

DocID: 1vdls - View Document

Microsoft Word - ST64 Cancer Immunotherapy v1.0.docx

DocID: 1uTyz - View Document

April 18, 2018 Torii Pharmaceutical Co., Ltd. Price Listing on the NHI Reimbursement List and Launch of “CEDARCURE® Japanese Cedar Pollen Sublingual Tablets”, an Allergen Immunotherapy Tablet for Japanese Cedar Poll

DocID: 1uM8x - View Document

第42回 日本免疫学会学術集会 クリニカルセミナー 2 Sublingual immunotherapy for Japanese cedar pollinosis

DocID: 1untY - View Document

President of ORPHEUS Robert Adam Harris Professor in Immunotherapy in Neuroinflammation Karolinska Institutet Personal details:

DocID: 1u6T9 - View Document